Psychiatry
Borderline Personality Disorder
35
Pipeline Programs↗
8
Active Trials↗
23
Companies Involved↗
Borderline personality disorder is a moderately active landscape with 35 programs across 23 companies. The most active players are Boehringer Ingelheim, Novartis, Lykos Therapeutics. 6 therapies are approved with 5 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical9
Phase 11
Phase 214
Phase 35
Analysis
Trial Status
44
clinical trials
Completed24 · 55%
Unknown status5 · 11%
Terminated4 · 9%
Recruiting4 · 9%
Not yet recruiting3 · 7%
Withdrawn2 · 5%
Other2 · 5%
Clinical Trials
Trial Activity
44 trials
A Novel Drug for Borderline Personality Disorder
Recruiting·—·Phase 2·NCT02097706·150 enrolled
Emotional Regulation and Impulsivity Among Adolescents with Borderline Personality Disorder
Active, not recruiting·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 2·NCT03209102·66 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)